Affordable Generic Weight-Loss Drugs Soon Available in India

India's anti-obesity pharmaceutical market is on the brink of a significant transformation. Following the expiration of the patent for semaglutide, the active ingredient in popular weight-loss drugs Wegovy and Ozempic, several pharmaceutical companies are set to introduce affordable generic versions. This change is expected to substantially reduce the cost of these treatments.

Market Expansion and Price Reduction

The patent for semaglutide expired on March 20, opening the market to over six pharmaceutical companies poised to launch their generic versions. Notable participants include Sun Pharma, Zydus Lifesciences, Dr. Reddy's, and Natco Pharma, all planning to release their products starting March 21. This influx is anticipated to drive down prices significantly, potentially halving the monthly treatment costs.

Currently, the Indian market for weight-loss drugs is valued at approximately Rs 1,400 crore. Analysts predict this market could double within a year due to the increased accessibility of lower-priced generics. The introduction of these affordable alternatives is expected to widen access, allowing more patients to benefit from these therapies.

Impact on the Pharmaceutical Landscape

The entry of multiple companies into the semaglutide market is set to intensify competition, which could further drive down prices over time. The availability of generics at an estimated 50% lower cost—around Rs 3,500 to Rs 4,000 per month for the starting dose—presents a substantial financial relief for patients.

The anti-diabetic therapy market, which has seen a growth of over 15% in January, is likely to benefit from these developments. The popularity of innovative therapies such as Eli Lilly’s Mounjaro has already spurred market growth, with sales reaching Rs 112 crore, according to Pharmarack.

Industry Reactions

Sun Pharma, a major player in the pharmaceutical industry, has expressed its commitment to enhancing access to generic semaglutide. Kirti Ganorkar, Managing Director of Sun Pharma, highlighted the company's readiness to enter the market on the first day of the patent expiry. Sun Pharma plans to offer its products in a user-friendly prefilled pen format, ensuring ample supply across India for both weight management and type 2 diabetes treatments.

Future Prospects

The introduction of generics marks a pivotal moment for India's pharmaceutical industry, particularly in the weight-loss segment. With the potential for a tenfold market expansion in the coming years, as competition grows, patients could benefit from more affordable and accessible treatment options.

As companies like Sun Pharma lead the charge in this market shift, the landscape of weight-loss treatment in India is set to evolve, promising broader access to essential therapies at reduced costs.